AG真人官方

Haemonetics Corp. (HAE) 鈥� Form 4 Insider Transaction

On 07/24/2025 director Diane M. Bryant received 2,693 restricted stock units (RSUs) under the company鈥檚 Amended & Restated 2019 LTIP. The award is coded 鈥淎鈥� (acquisition) and will vest 100 % on the first anniversary of the grant date. Each RSU converts into one common share upon vesting. Following the grant, Bryant鈥檚 total beneficial ownership increased to 7,126 directly held shares. No derivative securities were reported.

The filing represents routine board compensation; no purchase or sale of freely-trading shares occurred, and cash was not exchanged. Dilution impact is immaterial relative to Haemonetics鈥� 50 + million shares outstanding, but the grant reinforces director-shareholder alignment.

Portage Biotech Inc. (Nasdaq: PRTG) filed a Prospectus Supplement dated 27 June 2025 that incorporates its same-day Form 6-K. The filing establishes an At-The-Market (ATM) Offering Agreement with Rodman & Renshaw LLC, enabling the company to sell up to $3.38 million of ordinary shares from time to time. Sales may be executed on Nasdaq, in block or privately-negotiated transactions, or through other methods permitted under Rule 415(a)(4).

Key commercial terms include a 3.0 % cash commission on gross proceeds payable to the Agent, reimbursement of specified expenses, and customary representations, warranties and indemnification provisions. The ATM will automatically terminate when the full dollar limit is reached or upon earlier termination of the agreement.

The shares will be issued under the company鈥檚 effective shelf Registration Statement on Form F-3 (File No. 333-286961; declared effective 14 May 2025) and the related base prospectus plus this prospectus supplement (the 鈥淎TM Prospectus鈥�). The company鈥檚 ordinary shares last closed at $5.54 on 27 June 2025.

Investors are reminded that the offering involves a high degree of risk; relevant risk factors are detailed on page 9 of the November 7, 2023 base Prospectus and incorporated documents. No regulatory body has approved or disapproved the securities described.

Portage Biotech has entered into an At The Market (ATM) Offering Agreement with Rodman & Renshaw LLC on June 27, 2025. Through this agreement, Portage can offer and sell ordinary shares with an aggregate offering price of up to $3,377,250.

Key details of the ATM offering:

• Sales will be conducted through various methods including privately negotiated transactions, block transactions, and "at the market offerings" on Nasdaq Capital Market
• Rodman will receive a 3.0% commission on gross sales
• The offering will terminate upon reaching the full amount or early termination of the agreement
• Sales will be made under the shelf registration Form F-3 (File No. 333-286961) declared effective May 14, 2025

This strategic move provides Portage with flexibility in raising capital through controlled equity distributions. The filing includes legal opinions and necessary exhibits confirming the arrangement's compliance with securities regulations.

Portage Biotech has filed a prospectus supplement for an "at the market" offering of ordinary shares worth up to $3,377,250 through Rodman & Renshaw LLC as sales agent. The shares will be sold on the Nasdaq Capital Market (PRTG) where the last reported price was $5.96 per share on June 26, 2025.

Key offering details:

• Sales agent commission: Up to 3.0% of gross sales price
• Public float: Approximately $10,131,750 (855,000 shares at $11.85)
• Offering limitations: Cannot exceed one-third of public float ($3,377,250) in any 12-month period due to Form F-3 restrictions

The company, a clinical-stage immune-oncology firm developing first-in-class cancer therapies, recently faced operational challenges. In January 2024, they discontinued their iNKT program trial due to funding issues, and in April 2024 paused patient accrual for their adenosine trial program. This offering appears aimed at raising additional capital to support ongoing operations.

Portage Biotech (NASDAQ: PRTG) has filed a prospectus supplement related to 481,581 Ordinary Shares underlying Warrants. The key development is the company's regaining of compliance with Nasdaq's continued listing requirements, specifically the minimum stockholders' equity requirement for The Nasdaq Capital Market.

Key points from the filing:

• The company's stock closed at $5.60 on June 24, 2025 on Nasdaq
• The filing updates the original prospectus dated November 7, 2023, which is part of Form F-1 Registration No. 333-275229
• This supplement incorporates information from Form 6-K filed on June 25, 2025
• The company is a clinical-stage immuno-oncology firm developing novel biologics for cancer treatment

The filing includes standard risk disclaimers and forward-looking statements regarding financing, going concern status, and scientific results. The document is signed by CFO Andrea Park and includes incorporation by reference into Forms S-8 and F-3 registration statements.

Portage Biotech has successfully regained compliance with Nasdaq Capital Market's minimum stockholders' equity requirement, as announced in a Form 6-K filed on June 28, 2025. The company received official notice from Nasdaq on June 24, 2025, confirming their compliance status and closing the previously announced listing matter.

Key points from the filing:

• Filing incorporates by reference into Form S-8 (File No. 333-275842) and Form F-3 (File No. 333-286961) registration statements
• Company maintains its listing on the Nasdaq Capital Market
• Press release dated June 25, 2025, included as Exhibit 99.1
• Document signed by CFO Andrea Park

This development is significant for investors as it confirms Portage Biotech's continued compliance with Nasdaq listing requirements, ensuring maintained access to public markets and investor visibility.